Rudolf Maibach
YOU?
Author Swipe
View article: Local application of sodium thiosulfate as an otoprotectant for cisplatin-exposed patients – A narrative literature review to explore the potential benefit for children with cancer
Local application of sodium thiosulfate as an otoprotectant for cisplatin-exposed patients – A narrative literature review to explore the potential benefit for children with cancer Open
Background: Ototoxicity is a highly prevalent, serious, and irreversible side effect in cisplatin-treated childhood cancer patients, which can significantly impact speech-language development, psychosocial development, and quality of life.…
View article: Validation of the stratification for newly diagnosed hepatoblastoma: An analysis from the Children’s Hepatic tumors International Collaboration (CHIC) database
Validation of the stratification for newly diagnosed hepatoblastoma: An analysis from the Children’s Hepatic tumors International Collaboration (CHIC) database Open
Introduction: The Children’s Hepatic Tumors International Collaboration (CHIC) previously developed the CHIC hepatoblastoma risk stratification (CHIC-HS) model by analyzing the original CHIC dataset (development set). A validation of the r…
View article: Upfront or delayed surgery in resectable hepatoblastoma: analysis from the children’s hepatic tumors international collaboration database
Upfront or delayed surgery in resectable hepatoblastoma: analysis from the children’s hepatic tumors international collaboration database Open
European Network for Cancer Research in Children and Adolescents, funded through the Framework Program 7 of the European Commission; Children's Oncology Group Cure Search grant contributed by the Hepatoblastoma Foundation; Practical Resear…
View article: Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature
Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature Open
PURPOSE Hearing loss occurs in 50%-70% of children treated with cisplatin. Scientific efforts have led to the recent approval of a pediatric formula of intravenous sodium thiosulfate (STS) for otoprotection by the US Food and Drug Administ…
View article: The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution
The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution Open
Liver tumors account for approximately 2% of all pediatric malignancies. Children with advanced stages of hepatoblastoma (HB) are cured only 50-70% of the time while children with advanced hepatocellular carcinoma (HCC) have a <20% 5-year …
View article: Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response Open
Background and Aims: Hepatoblastoma (HB) is the predominant form of pediatric liver cancer, though it remains exceptionally rare. While treatment outcomes for children with HB have improved, patients with advanced tumors face limited thera…
View article: Consensus classification of pediatric hepatocellular tumors: A report from the Children's Hepatic tumors International Collaboration (CHIC)
Consensus classification of pediatric hepatocellular tumors: A report from the Children's Hepatic tumors International Collaboration (CHIC) Open
Background Liver tumors are rare in children with histologic heterogeneity that makes diagnosis challenging. Systematic histopathological review, performed as part of collaborative therapeutic protocols, identified relevant histologic subt…
View article: Supplementary Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Supplementary Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma Open
Supplementary Figures and Tables
View article: Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma Open
Management of hepatoblastoma (HB), the most frequent pediatric liver cancer, is based on surgical resection and perioperative chemotherapy regimens. In this study, we aimed to identify actionable targets in HB and assess the efficacy of mo…
View article: Supplementary Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Supplementary Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma Open
Supplementary Figures and Tables
View article: Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma Open
Management of hepatoblastoma (HB), the most frequent pediatric liver cancer, is based on surgical resection and perioperative chemotherapy regimens. In this study, we aimed to identify actionable targets in HB and assess the efficacy of mo…
View article: Supplementary Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Supplementary Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma Open
Supplementary Figures and Tables
View article: Supplementary Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Supplementary Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma Open
Supplementary Figures and Tables
View article: Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Data from Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma Open
Management of hepatoblastoma (HB), the most frequent pediatric liver cancer, is based on surgical resection and perioperative chemotherapy regimens. In this study, we aimed to identify actionable targets in HB and assess the efficacy of mo…
View article: Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it
Sodium thiosulfate as cisplatin otoprotectant in children: The challenge of when to use it Open
Cisplatin is an essential chemotherapeutic agent for children treated with hepatic tumors, neuroblastoma, medulloblastoma, germ cell tumors, and osteosarcoma. Unfortunately, cisplatin-induced hearing loss (CIHL) occurs in about 50% of trea…
View article: Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma
Identification of <i>IGF2</i> as Genomic Driver and Actionable Therapeutic Target in Hepatoblastoma Open
Management of hepatoblastoma (HB), the most frequent pediatric liver cancer, is based on surgical resection and perioperative chemotherapy regimens. In this study, we aimed to identify actionable targets in HB and assess the efficacy of mo…
View article: Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC)
Outcomes of Patients Treated for Hepatoblastoma with Low Alpha-Fetoprotein and/or Small Cell Undifferentiated Histology: A Report from the Children’s Hepatic Tumors International Collaboration (CHIC) Open
Small cell undifferentiated (SCU) histology and alpha-fetoprotein (AFP) levels below 100 ng/mL have been reported as poor prognostic factors in hepatoblastoma (HB); subsequent studies reported SMARCB1 mutations in some SCU HBs confirming t…
View article: Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant Open
View article: A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients
A combined clinical and biological risk classification improves prediction of outcome in hepatoblastoma patients Open
We propose a new stratification system based on the combination of clinical factors and the 16-gene signature, which may facilitate a risk-adapted management of HB patients.
View article: The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database
The importance of age as prognostic factor for the outcome of patients with hepatoblastoma: Analysis from the Children's Hepatic tumors International Collaboration (CHIC) database Open
Purpose Treatment outcomes for hepatoblastoma have improved markedly in the contemporary treatment era, principally due to therapy intensification, with overall survival increasing from 35% in the 1970s to 90% at present. Unfortunately, th…
View article: Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial Open
View article: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial Open
View article: Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial Open
PURPOSE To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as ne…
View article: Sodium Thiosulfate and Cisplatin-Induced Hearing Loss
Sodium Thiosulfate and Cisplatin-Induced Hearing Loss Open
View article: Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss Open
The addition of sodium thiosulfate, administered 6 hours after cisplatin chemotherapy, resulted in a lower incidence of cisplatin-induced hearing loss among children with standard-risk hepatoblastoma, without jeopardizing overall or event-…
View article: Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer Open
Among premenopausal women with breast cancer, the addition of ovarian suppression to tamoxifen resulted in significantly higher 8-year rates of both disease-free and overall survival than tamoxifen alone. The use of exemestane plus ovarian…
View article: A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial
A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial Open
View article: PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer
PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer Open
View article: Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients
Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients Open
View article: Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial Open